These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19304304)

  • 21. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.
    Bao Q; Zhou J
    Eur J Med Chem; 2023 Mar; 250():115188. PubMed ID: 36773550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
    Hosseini I; Mac Gabhann F
    PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.
    Farrow MA; Sheehy AM
    Future Microbiol; 2008 Apr; 3(2):145-54. PubMed ID: 18366335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
    Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
    Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOBEC proteins and intrinsic resistance to HIV-1 infection.
    Malim MH
    Philos Trans R Soc Lond B Biol Sci; 2009 Mar; 364(1517):675-87. PubMed ID: 19038776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
    Sadler HA; Stenglein MD; Harris RS; Mansky LM
    J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
    Ara A; Love RP; Chelico L
    PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
    Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
    J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction.
    Widera M; Hillebrand F; Erkelenz S; Vasudevan AA; Münk C; Schaal H
    Retrovirology; 2014 Aug; 11():72. PubMed ID: 25169827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.
    Kobayashi T; Koizumi Y; Takeuchi JS; Misawa N; Kimura Y; Morita S; Aihara K; Koyanagi Y; Iwami S; Sato K
    J Virol; 2014 May; 88(10):5881-7. PubMed ID: 24623435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif.
    Shao Q; Wang Y; Hildreth JE; Liu B
    J Virol; 2010 May; 84(9):4840-4. PubMed ID: 20147392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.